Alexion rebuilding pipeline with big data deals
August 10, 2017 – Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is rebuilding its early stage pipeline with two new deals focused on driving rare disease discovery with big genomic data. The company partnered with Sema4 (New York, N.Y.) for genomic sequencing and licensed the Reverse Engineering and Forward Simulation (REFS) platform from GNS Healthcare Inc. (Cambridge, Mass.) to accelerate development of new rare disease therapeutics.